Qiagen (QGEN) Competitors

$33.00 -0.29 (-0.86%)

Closing price 05/15/2026 03:59 PM Eastern

Extended Trading

$32.98 -0.02 (-0.07%)

As of 05/15/2026 04:44 PM Eastern

QGEN vs. BNTX, INSM, MRNA, ROIV, and VTRS

Should you buy Qiagen stock or one of its competitors? MarketBeat compares Qiagen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qiagen include BioNTech (BNTX), Insmed (INSM), Moderna (MRNA), Roivant Sciences (ROIV), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Qiagen compare to BioNTech?

Qiagen (NYSE:QGEN) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Qiagen has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.10B	3.24	$424.88M	$1.91	17.28
BioNTech	$2.81B	8.07	-$1.29B	-$5.88	N/A

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Qiagen pays an annual dividend of $0.35 per share and has a dividend yield of 1.1%. BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.7%. Qiagen pays out 18.3% of its earnings in the form of a dividend. BioNTech pays out -26.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. BioNTech is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Qiagen and Qiagen both had 9 articles in the media. Qiagen's average media sentiment score of 0.25 beat BioNTech's score of 0.12 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen currently has a consensus target price of $46.38, indicating a potential upside of 40.53%. BioNTech has a consensus target price of $130.60, indicating a potential upside of 45.84%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Qiagen has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Qiagen has a net margin of 19.16% compared to BioNTech's net margin of -44.39%. Qiagen's return on equity of 14.40% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
BioNTech	-44.39%	-5.30%	-4.62%

Summary

BioNTech beats Qiagen on 9 of the 17 factors compared between the two stocks.

How does Qiagen compare to Insmed?

Insmed (NASDAQ:INSM) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Qiagen has a net margin of 19.16% compared to Insmed's net margin of -144.44%. Qiagen's return on equity of 14.40% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Qiagen	19.16%	14.40%	8.40%

Insmed presently has a consensus target price of $210.95, indicating a potential upside of 93.29%. Qiagen has a consensus target price of $46.38, indicating a potential upside of 40.53%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Qiagen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.01	-$1.28B	-$5.75	N/A
Qiagen	$2.10B	3.24	$424.88M	$1.91	17.28

70.0% of Qiagen shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Insmed has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

In the previous week, Insmed had 11 more articles in the media than Qiagen. MarketBeat recorded 20 mentions for Insmed and 9 mentions for Qiagen. Insmed's average media sentiment score of 0.68 beat Qiagen's score of 0.25 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Qiagen beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Qiagen compare to Moderna?

Moderna (NASDAQ:MRNA) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Qiagen has a net margin of 19.16% compared to Moderna's net margin of -143.55%. Qiagen's return on equity of 14.40% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Qiagen	19.16%	14.40%	8.40%

Moderna presently has a consensus target price of $35.73, indicating a potential downside of 27.13%. Qiagen has a consensus target price of $46.38, indicating a potential upside of 40.53%. Given Qiagen's stronger consensus rating and higher possible upside, analysts plainly believe Qiagen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Qiagen has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.20B	8.83	-$2.82B	-$8.15	N/A
Qiagen	$2.10B	3.24	$424.88M	$1.91	17.28

Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

In the previous week, Moderna had 13 more articles in the media than Qiagen. MarketBeat recorded 22 mentions for Moderna and 9 mentions for Qiagen. Moderna's average media sentiment score of 0.73 beat Qiagen's score of 0.25 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	13 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Qiagen beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Qiagen compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Qiagen has a net margin of 19.16% compared to Roivant Sciences' net margin of -6,079.94%. Qiagen's return on equity of 14.40% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-6,079.94%	-19.04%	-18.15%
Qiagen	19.16%	14.40%	8.40%

Qiagen has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$29.05M	721.61	-$171.98M	-$1.17	N/A
Qiagen	$2.10B	3.24	$424.88M	$1.91	17.28

Roivant Sciences has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Roivant Sciences presently has a consensus target price of $30.55, indicating a potential upside of 4.30%. Qiagen has a consensus target price of $46.38, indicating a potential upside of 40.53%. Given Qiagen's higher possible upside, analysts plainly believe Qiagen is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Qiagen had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 9 mentions for Qiagen and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.48 beat Qiagen's score of 0.25 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Qiagen beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does Qiagen compare to Viatris?

Viatris (NASDAQ:VTRS) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.9%. Qiagen pays an annual dividend of $0.35 per share and has a dividend yield of 1.1%. Viatris pays out -184.6% of its earnings in the form of a dividend. Qiagen pays out 18.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

Qiagen has a net margin of 19.16% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Qiagen	19.16%	14.40%	8.40%

79.9% of Viatris shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Viatris has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

Qiagen has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.56B	1.32	-$3.51B	-$0.26	N/A
Qiagen	$2.10B	3.24	$424.88M	$1.91	17.28

In the previous week, Viatris had 2 more articles in the media than Qiagen. MarketBeat recorded 11 mentions for Viatris and 9 mentions for Qiagen. Viatris' average media sentiment score of 0.73 beat Qiagen's score of 0.25 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viatris presently has a consensus target price of $15.71, indicating a potential downside of 4.65%. Qiagen has a consensus target price of $46.38, indicating a potential upside of 40.53%. Given Qiagen's stronger consensus rating and higher possible upside, analysts clearly believe Qiagen is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Qiagen beats Viatris on 10 of the 18 factors compared between the two stocks.

Get Qiagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QGEN vs. The Competition

Export

Metric	Qiagen	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$6.80B	$3.31B	$6.37B	$22.74B
Dividend Yield	0.79%	2.32%	2.80%	4.11%
P/E Ratio	17.24	18.50	20.66	29.73
Price / Sales	3.24	184.42	532.07	40.03
Price / Cash	9.69	121.77	42.43	24.79
Price / Book	2.04	6.63	9.87	4.60
Net Income	$424.88M	$24.40M	$3.57B	$1.06B
7 Day Performance	-0.13%	4.14%	0.23%	-2.27%
1 Month Performance	-19.97%	-4.80%	-2.54%	-1.66%
1 Year Performance	-26.49%	62.87%	33.54%	21.94%

Qiagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QGEN Qiagen	4.5542 of 5 stars	$33.00 -0.9%	$46.38 +40.5%	-26.5%	$6.80B	$2.10B	17.24	5,654	Dividend Increase Analyst Downgrade
BNTX BioNTech	3.7599 of 5 stars	$93.34 -0.8%	$131.60 +41.0%	-3.5%	$23.80B	$3.25B	N/A	7,807	Analyst Forecast Buyback Announcement
INSM Insmed	3.1499 of 5 stars	$103.89 +2.5%	$211.86 +103.9%	+60.2%	$21.97B	$606.42M	N/A	1,664	Analyst Forecast Analyst Revision High Trading Volume
MRNA Moderna	1.6047 of 5 stars	$52.88 -2.7%	$35.73 -32.4%	+97.3%	$21.57B	$1.94B	N/A	4,700	High Trading Volume
ROIV Roivant Sciences	2.022 of 5 stars	$28.96 +1.4%	$30.55 +5.5%	+171.5%	$20.44B	$29.05M	N/A	860	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:QGEN) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qiagen (QGEN) Competitors